Cash and cash equivalents were $208.5 million as of June 30, 2025, compared to $302.1 million as of December 31, 2024. Wave expects that its current cash and cash equivalents will be sufficient to fund operations into 2027. Potential future milestones and other payments to Wave under its GSK collaboration are not included in its cash runway.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Optimistic Buy Rating for Wave Life Sciences Driven by Promising AATD Treatment Developments and RNA Editing Technology Potential
- Wave Life Sciences initiated with an Outperform at Oppenheimer
- Wave Life Sciences initiated with a Buy at Citi
- Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating
- Wave Life Sciences: Promising RNA Editing Developments and Positive Stock Outlook